Sebaceous neoplasms are commonly considered in their relationship to the Muir-Torre syndrome and the now well-documented loss of DNA mismatch repair proteins leading to microsatellite instability. However, sebaceous neoplasms showing microsatellite instability comprise only a subset of this group of tumors, and thus, alternative tumorigenic mechanisms must exist. This article explores the relationship of p53, a tumor suppressor implicated in other cutaneous malignancies, and sebaceous neoplasia. We examined 94 sebaceous tumors from 92 patients. Tumors with strong nuclear p53 staining were significantly associated with the diagnosis of sebaceous carcinoma compared with benign sebaceous lesions, most notably for periocular carcinomas. Importantly, nuclear mismatch repair protein expression was intact in all lesions showing p53 alterations, suggesting that p53 dysfunction may represent a divergent pathway in the molecular pathogenesis of these tumors.
INTRODUCTION
Numerous signaling pathways and genetic mutations have been implicated in tumor biology. Cutaneous sebaceous neoplasms comprise a group of lesions for which one particular pathway of tumorigenesis has been extensively studied, in part, because of their association with the Muir-Torre syndrome (MTS). MTS refers to the association of cutaneous sebaceous neoplasia and internal visceral malignancies, most frequently colonic adenocarcinoma. [1] [2] [3] Patients with MTS comprise a small subset of patients (less than 5%) with hereditary nonpolyposis colorectal cancer syndrome, an autosomal dominant condition defined by mutation of one of several genes encoding DNA mismatch repair proteins. In MTS, most commonly MSH2 is affected and less frequently MLH1 or other members of this family such as MSH6 are affected; in nonpolyposis colorectal cancer, MLH1 and MSH2 are equally affected. [4] [5] [6] The germline mutation, coupled with a second somatic mutation, results in defective repair of DNA base pair replication errors. These are most commonly encountered in short stretches of DNA characterized by repetitive mono-or dinucleotide repeats, termed microsatellites. Microsatellite instability predisposes patients to development of numerous tumors, including sebaceous neoplasms. 7, 8 Interestingly, several reports have proposed that specific characteristics of sebaceous tumor type, location, and histology may predict deficiency in mismatch repair enzymes, microsatellite instability, and MTS. 9, 10 In keeping with the distribution of normal sebaceous glands, sebaceous tumors are most often found in the head and neck region. However, 2 groups have reported that mismatch repair deficiency is statistically more common in sebaceous tumors occurring outside the head and neck region. 11, 12 Furthermore, tumor type has been correlated to mismatch repair status, with nearly half of benign sebaceous tumors (adenomas and sebaceomas) displaying deficiencies in mismatch repair enzymes compared with only 15% of sebaceous carcinomas. More specifically, carcinomas in the head and neck region were shown to exhibit even less-frequent mismatch repair deficiency. 11 So, although mismatch repair deficiency within sebaceous lesions certainly plays a role in the pathogenesis of some of these tumors, it is clear that mechanisms beyond microsatellite instability must contribute to tumorigenesis in a subset of sebaceous lesions.
p53 is a well-described tumor suppressor gene, whose loss is implicated in a myriad of cancers. [13] [14] [15] Normally kept at low levels within the cell, p53 is activated by cell stressors such as oxidative stress and DNA damage to regulate the transcription of genes, which protect the cell from further damage, including activation of DNA repair pathways and cell cycle arrest. 13 The majority of P53 mutations occur in the DNA binding domain, resulting in impaired downstream regulation of cell cycle control and faulty or absent repair of DNA damage. Ultraviolet (UV) radiation leads to the development of specific ''signature'' P53 mutations and has been linked to various cutaneous cancers. 13, 16 Although limited research exists currently on the relationship of P53 mutations and sebaceous neoplasms, [17] [18] [19] [20] p53 represents a potential factor in tumor initiation or progression. Immunohistochemical staining for nuclear p53 is often increased in tumors with P53 mutations. Although nuclear overexpression is not specific for mutations in the P53 gene, it seems to correlate with dysregulation of the signaling pathway, thus representing a reasonable method to investigate integrity of the p53 pathway. 21, 22 The relationship of p53 dysregulation and microsatellite instability in sebaceous neoplasia has not been investigated.
The goal of this study was to determine the frequency of p53 impairment as assessed by strong nuclear p53 immunohistochemical staining within sebaceous neoplasms and to correlate these findings with DNA mismatch repair status, tumor site, and tumor histology.
MATERIALS AND METHODS

Cases
This study utilized a large case series of sebaceous neoplasms that are previously described. 11 The local institutional review board approved this study with a waiver of consent. Briefly, the tumors included 17 sebaceous hyperplasias serving as controls, 13 sebaceomas, 46 sebaceous adenomas, and 35 sebaceous carcinomas [both periocular (n = 10) and nonocular (n = 22); site was unknown for 3 carcinomas]. The criteria for diagnosis of each lesion were based on previously described criteria, with diagnoses reviewed and confirmed by 3 of the authors (A.J.L., S.C.S., and E.C.; A.J.L., American and E.C., British board-certified dermatopathologists). Sebaceous adenomas were defined as benign lesions with maintained organoid architecture, an increased basaloid cell population compared with sebaceous hyperplasia, but greater than 50% mature sebocyte differentiation. 23 Sebaceomas, also benign lesions, had a loss of organoid architecture and more extensive (.50%) basaloid cell content compared with adenomas. [24] [25] [26] Sebaceous carcinomas exhibited malignant features such as infiltrative architecture and/or cytologic atypia to a degree unacceptable in a benign lesion. 27 Cystic change and keratoacanthoma-like architecture were assessed according to prior descriptions of these features. [28] [29] [30] Patient demographics and tumor location were obtained from pathology reports.
Immunohistochemistry for p53 Nuclear Localization
Immunohistochemistry for p53 (clone DO7, dilution 1:100; DakoCytomation) was performed on formalin-fixed paraffin-embedded sections. Microscopically, p53 staining was assessed as absent, some staining, or uniform nuclear staining. Some staining included patterns of weak nuclear and/or cytoplasmic staining in scattered cells. These patterns of staining generally do not correlate with mutated or dysfunctional p53. 21, 31, 32 Staining was only considered positive and significant if there was strong uniform nuclear staining in the majority of the tumor cells, clearly distinct from surrounding nonneoplastic tissue. This pattern of staining has been most closely linked to the identification of (predominately missense) p53 mutations or other dysfunction of this pathway. 21, 31 The immunohistochemistry for mismatch repair enzymes MSH2, MLH1, and MSH6 was previously described and reported. 11 
Statistical Analysis
For purposes of statistical analysis, patient demographics and tumor characteristics were summarized using tabulations for categorical variable and means and SDs for continuous variables. Relationships among categorical variables were assessed using the x 2 test for equal proportions or Fisher exact test as appropriate. Associations between age and categorical variables were determined using the unpaired Student t test or 1-way analysis of variance. All reported P values were 2 sided and reported at a significant level of 5%. Analyses were performed with SAS statistical software (release 8.2).
RESULTS
The analysis included 111 cases. These included 17 cases of sebaceous hyperplasia those were used as controls for the staining methods and were not a part of the primary analysis. There were 94 sebaceous neoplasms from 92 patients. Two patients had 2 tumors each. The diagnoses and immunohistochemical results were identical in both specimens from each of these 2 patients. The diagnoses for the 94 specimens comprised 46 adenomas (49%), 13 sebaceomas (14%), and 35 carcinomas (37%).
Patient Characteristics and Immunohistochemistry
Seventeen cases of sebaceous hyperplasia from the head and neck served as controls. For 15 of these cases, p53 staining was completely absent, whereas there was minimal weak staining for 2 cases (scattered nuclei).
As previously reported, 11 demographic information of age and sex was known in 80 of the 92 patients with sebaceous lesions. Forty-seven (59%) were male and 33 (41%) were female. Patient age ranged from 34 to 94 years with a mean age of 70 years (SD, 14.7 years). Additional patient information, such as history of nonsebaceous skin cancers or visceral malignancy, was not available.
For the 94 specimens, tumor site was unavailable for 15 tumors (16%): 11 adenomas, 1 sebaceoma, and 3 carcinomas. Of the remaining 79 tumors, 82% were located in the head and neck region. Fourteen tumors (18%) occurred outside the head and neck area. The group of benign sebaceous neoplasms (adenomas and sebaceomas) was composed of 39 tumors in the head and neck region and 8 tumors located elsewhere. Of the sebaceous carcinomas, 26 tumors were located in the head and neck region and 6 were located elsewhere. Of head and neck sebaceous carcinomas, 10 were periocular and 16 were extraocular. As with previous reports, 22, 33, 34 there was a significant association between periocular tumors and diagnosis (P = 0.0223), with 10 of 14 periocular tumors (71%) diagnosed as carcinomas.
Of the 94 specimens, 9 tumors (9.6%) demonstrated uniform strong staining with p53. These tumors, considered to have a dysfunctional p53 pathway (and possibly mutated p53), comprised 8 carcinomas (4 periocular) and 1 sebaceoma. Of these p53-positive tumors, tumor site was unknown in 2 carcinoma specimens; the remaining 7 tumors were located in the head and neck region.
p53 staining was not statistically related to patient age or sex.
Association of p53 Staining and Tumor Location
In the subset of tumors from the head and neck (n = 65), 7 specimens stained uniformly for p53 (11%; n = 7 of 65). No tumor from a non-head and neck region was positive for p53 staining (0%; n = 0 of 14) ( Fig. 1 ). When these two groups were compared, there was not a statistically significant difference (P = 0.2446), likely due to the small numbers of p53-positive specimens. However, there was a statistically significant percentage of tumors from the periocular region compared with the extraocular region (P = 0.0201). Out of 14 periocular tumors (10 of which were carcinomas), 4 tumors (29%), all carcinomas, stained uniformly for p53. In contrast, only 3 of 61 extraocular tumors (5%) stained uniformly for p53. This result is likely due to the prevalence of carcinomas in the periocular region.
Association of p53 Staining and Diagnosis
Uniform strong p53 staining was significantly associated with diagnosis. Benign sebaceous lesions (adenomas and sebaceomas) showed low rates of p53 staining (1.7%; n = 1 of 59), whereas carcinomas were more likely to stain uniformly for p53 (23%; n = 8 of 35; P = 0.0008 by x 2 test). The statistical significance carried over to individual diagnosis of adenoma, sebaceoma, and carcinoma as well, as determined by Fisher exact test (P = 0.0014). No adenomas demonstrated strong uniform p53 staining (0%; n = 0 of 46) and only 1 sebaceoma showed uniform p53 staining (7.7%; n = 1 of 13), but 8 of 35 carcinomas (23%) showed uniform p53 staining ( Table 1 and Figs. 2, 3 ).
Association of p53 Staining and Mismatch Repair Enzyme Status
p53 staining results were significantly associated with mismatch repair enzyme status (P = 0.0432). Strong uniform nuclear p53 staining (n = 9) occurred only in specimens with intact mismatch repair protein expression, as assessed by immunohistochemistry (Table 1) . FIGURE 1. Of 32 sebaceous carcinomas for which tumor site was known, 26 were located on the head and neck, whereas 6 were located elsewhere on the body. All carcinomas demonstrating p53 mutations for which tumor site was known were located in the head and neck region with a preponderance of p53 mutations found in periocular tumors (solid dark circles). In contrast, carcinomas showing mismatch repair protein deficiency (hatched circles) tended to be in non-head and neck locations. In addition to the tumors illustrated here, only 3 other tumors showed strong uniform p53 staining: 1 sebaceoma from the cheek and 2 additional carcinomas for which tumor site was not known. 
DISCUSSION
It is well established that a subset of sebaceous lesions harbor microsatellite instability and mutations in proteins encoding DNA mismatch repair enzymes. 8, 11, 12, 35, 36 However, the presence of mismatch repair deficiency has been shown to occur less frequently in carcinomas than in benign sebaceous lesions and is seen more commonly in tumors occurring outside of the head and neck region. 11, 12 Therefore, there are clearly other mechanisms contributing to the development of sebaceous lesions, particularly carcinomas.
Moreover, the head, neck, and periorbital regions are exposed to frequent UV radiation, potentially making this an attractive factor in tumorigenesis of sebaceous neoplasia. Mutation of p53 and signaling alterations secondary to UV radiation, 13, 37 the presence of p53 mutations in other nonmelanoma skin cancers, 13, 16 and previous reports noting p53 staining in sebaceous carcinomas are well documented. [17] [18] [19] [20] Aberrant or absent p53 signaling seems to represent a potential mediator of an alternative mechanism of malignant sebaceous tumorigenesis (distinct from the microsatellite instability pathway). Proponents of field cancerization theory have demonstrated that numerous p53 clonal mutations occur as a result of chronic sun damage within the epidermis and can be present in ''normal'' appearing skin, thus putting patients at risk for the developing multiple skin cancers. The development of nonmelanoma skin cancers is suggested to occur when P53 mutations involve the stem cell compartment of the epidermal proliferative unit. 38, 39 Interestingly, however, although a recent study by Kiyosaki et al 20 found a high percentage of p53 mutations in a small group of eyelid sebaceous carcinomas, the mutations were not the typical tandem mutations induced by UV damage. This finding raises the possibility that p53 dysregulation as a mechanism of sebaceous tumorigenesis may occur independent of UV damage. Indeed, periocular sebaceous carcinomas, which demonstrated the highest incidence of p53 nuclear staining in the present study, can often present on the conjunctival aspect of the eyelid, which is largely protected from solar damage.
The present study examined the relationship between tumor type and site with p53 dysregulation in sebaceous neoplasms as assessed by p53 immunohistochemistry. Intense nuclear p53 signal was significantly associated with tumor location (P = 0.0201), occurring more frequently in the periocular region, and was significantly correlated with tumor type (P = 0.0008), occurring almost exclusively in sebaceous carcinomas. Importantly, specimens demonstrating p53 staining showed intact DNA mismatch repair enzyme status, suggesting that p53 signaling alterations may represent an independent and distinct mechanism in the development of sebaceous carcinomas.
Previous reports have suggested alterations in p53 signaling as contributing to the pathogenesis of sebaceous lesions and reported p53 staining within these tumors. [17] [18] [19] Gonzalez-Fernandez et al examined a set of periocular sebaceous carcinomas, reporting p53 overexpression in 5 of 5 invasive sebaceous carcinomas. Two cases that were negative for p53 were diagnosed as in situ carcinomas without an invasive component. 17 The high frequency of p53 positivity in their study may be accounted for by the selection of only a limited number of periocular carcinomas for study. It does, however, correspond to our findings that this particular subset of sebaceous lesions is most likely to show p53 overexpression.
McBride et al examined a spectrum of sebaceous lesions, noting strong p53 overexpression in sebaceous carcinomas. However, this study did not comment on how many of the 12 carcinomas examined showed p53 staining, nor did it comment on whether tumor location impacted p53 staining. 18 Moreover, benign sebaceous lesions examined in this study were also reported to have some degree of p53 staining, albeit in a fainter and topographically restricted pattern. Cabral et al examined 27 benign and malignant sebaceous lesions. They found statistically significant increased percentages of p53-positive cells in carcinomas compared with adenomas and a trend for the intensity of p53 staining to be greater in carcinomas compared with benign lesions. 19 Of the 8 sebaceous carcinomas examined, only 1 was periocular. Studies by McBride et al and Cabral et al differed from the present one in that p53 staining was assessed on a continuum, without a strict categorical definition for positive staining. In the present study, focal or weak p53 staining was observed in 41% (n = 38) of the specimens (data not shown); however, a strict criteria of strong uniform nuclear staining in the majority of cells was used to designate ''positive staining,'' as this pattern has been shown to correlate more closely with clonal P53 mutations and/or disruption of the p53 signaling network. 21, 31 Our study confirms previous reports that p53 is overexpressed in a subset of sebaceous tumors. This study expands the current body of knowledge by establishing a firm link between p53 dysregulation and the diagnosis of sebaceous carcinoma. Nearly one-quarter of examined carcinomas showed p53 staining, whereas all adenomas were negative and only 1 sebaceoma was positive. Because the number of specimens examined in this study is larger than that in previous similar studies, this study likely approximates the true incidence of p53 mutation and the frequency with which it is seen within subsets of sebaceous neoplasia. Our study also demonstrates a strong association between p53 dysregulation and periocular tumor location. However, this may be related to the overall increased prevalence of carcinomas in the periocular region. For the 7 p53 staining sebaceous tumors for which the tumor site was known, all were located in the head and neck region, and 4 were periocular. Interestingly, 4 of 10 periocular carcinomas had nuclear p53 accumulation, compared with 4 of 25 nonocular carcinomas, indicating a propensity for p53 dysregulation in the periocular region. Moreover, although intense p53 nuclear accumulation was more common in the periocular carcinomas, it was also seen in nonocular carcinomas, suggesting that p53 dysregulation may be a marker of ''invasive'' or ''malignant'' tumorigenesis. This idea is substantiated by results from a previous study noting P53 mutations in invasive periocular sebaceous carcinomas but not in in situ lesions. 17 We lack a credible explanation for the single sebaceoma case with intense nuclear p53 reactivity. However, it is interesting to speculate that in this singular sebaceoma, perhaps, a second mutation, downstream or in parallel of p53 signaling, counteracted some of the ''malignant'' effects of the loss of p53 but still allowed proliferation of a benign neoplasm. Alternatively P53 mutation by itself may be insufficient to effect a malignant phenotype.
Finally, this study also compared p53 staining with expression of DNA mismatch repair proteins in sebaceous lesions, which correlates strongly with microsatellite instability and drives the phenotype in the MTS. Notably, in all sebaceous lesions with p53 overexpression, mismatch repair proteins were intact, confirming microsatellite stability. These data suggest that divergent signaling mechanisms can contribute to sebaceous neoplasia. Whereas microsatellite instability may be one pathway whereby sebaceous tumors arise or progress, p53 signaling alteration may be another. Microsatellite instability and its concomitant downstream effectors may be particularly important for the development of benign sebaceous lesions, 11 although the present data suggest that mutations in P53 may be more important in the development of malignancy and/or invasiveness. Importantly, this finding generally supports the widely held notion that benign sebaceous neoplasms are not premalignant lesions; if this was the case, one would expect to see more of an overlap between p53 staining and loss of mismatch repair protein expression, rather than independent molecular signatures.
Interestingly, a recent study specifically examined periocular sebaceous carcinomas in patients with concurrent visceral malignancy (a MTS phenotype) and found that the fragile histidine triad gene (FHIT) was disrupted in a subset of cases with confirmed microsatellite stability. 35 The authors suggested that mutations in FHIT provided another mechanism for sebaceous carcinoma formation. Similar in some ways to p53, Fhit (the protein product of FHIT) has been linked to apoptosis, with FHIT mutations resulting in defective programmed cell death. 40 Of note, another recent study documented a gain of function mutation in P53 in a sebaceous carcinoma with concomitant mutations in fragile sites, 41 thus perhaps linking FHIT and P53 as similar or even synergistic in their mechanism of tumorigenesis. Additional literature regarding the relationship of Fhit and p53 is lacking, and links between the 2 tumor suppressors and their individual contributions to the development of sebaceous tumors require more investigation.
A limitation of this study is that immunohistochemistry was used as a marker for P53 mutation. The tumors were not sequenced for the presence of specific p53 genetic mutations. Previous reports have correlated the presence of compact uniform nuclear staining for p53 with clonal mutations in the gene sequence. 21, 22 However, although nuclear accumulation of the p53 protein product, as assessed by immunohistochemistry, correlates with the presence of P53 mutations, immunohistochemistry may not detect all mutant p53 forms, null or frameshift mutations, nor will it pick up mutations in the gene that alter the signaling pathways but do not cause nuclear accumulation. 15, 42 In this regard, our study may underestimate sebaceous lesions with P53 mutations. Likewise, overestimation of P53 mutations may also occur because immunohistochemistry for p53 may actually detect mutations in proteins upstream or downstream of p53, which led to nuclear accumulation of the protein. 15, 22 Even in this case, the nuclear accumulation of p53 suggests a dysregulation of the signaling pathways involving p53 if not a mutation in the gene itself.
In conclusion, this study strongly suggests that p53 overexpression occurs in a set of primarily malignant sebaceous tumors that are microsatellite stable, particularly carcinomas in the periocular region, and provides a framework for future investigation of the role of P53 mutations in the pathogenesis of sebaceous tumors. Although DNA mismatch repair proteins and microsatellite instability receive much focused attention in sebaceous lesions because of linkage to the MTS, mutations in these genes account for only a subset of these tumors. In addition to establishing a clear relationship of tumor type and site to p53 overexpression, this study also provides evidence that P53 mutations are seen independent of microsatellite instability. Determination of specific p53 mutations within sebaceous tumors, particularly periocular sebaceous carcinomas, along with affected downstream targets and effectors may allow us to better dissect out the molecular mechanisms contributing to the development of these lesions.
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